Healthcare Management Solutions Ltd

hcsolutions.co.uk

Centrally based just south of Birmingham, HCMS has a nationwide team of Regional Managers, all of whom have had multi-site management experience and therefore have both practical experience and knowledge of day to day care home operation. We operate the lowest ratios of homes to Regional Managers in the industry recognising the intensive nature of the service that we offer.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AVENUEB CREATES A PATH TO SUCCESS FOR BIOLOGY STUDENTS

UC Davis | April 14, 2020

news image

The Genentech Foundation has donated $2.5 million to the University of California, Davis, College of Biological Sciences — the college’s largest single gift ever — to fund a program that will help biology students transferring from community college. Called AvenueB, the program will provide financial support and preparatory programs for students going to four-year university. According to the Campaign for College Opportunity, students transferring from community colleges to a U...

Read More

PROVENTION BIO AND VACTECH ANNOUNCE PUBLICATION OF PROOF-OF-CONCEPT DATA FOR COXSACKIEVIRUS B VACCINE

Provention Bio, Inc. | May 19, 2020

news image

The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models. Results provide a solid scientific basis for human trials with Provention's PRV-101 vaccine. Read More

EX-PFIZER ONCOLOGY R&D LEAD LANDS AT FIERCE 15 WINNER VIVIDION THERAPEUTICS

FierceBiotech | February 11, 2020

news image

Pfizer’s former longtime cancer research head Robert Abraham, Ph.D., has become the new chief scientific officer at a San Diego biotech after leaving the Big Pharma last year. He moves over to 2017 Fierce 15 winner Vividion Therapeutics, a biotech looking to increase the number of proteins small molecules can target. Last April, it got off a $82 million series B financing round. Its platform is based on the work of Benjamin Cravatt, Phil Baran and Jin-Quan Yu at the Scripps Research Instit...

Read More

INDUSTRIAL IMPACT

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

news image

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More
news image

AVENUEB CREATES A PATH TO SUCCESS FOR BIOLOGY STUDENTS

UC Davis | April 14, 2020

The Genentech Foundation has donated $2.5 million to the University of California, Davis, College of Biological Sciences — the college’s largest single gift ever — to fund a program that will help biology students transferring from community college. Called AvenueB, the program will provide financial support and preparatory programs for students going to four-year university. According to the Campaign for College Opportunity, students transferring from community colleges to a U...

Read More
news image

PROVENTION BIO AND VACTECH ANNOUNCE PUBLICATION OF PROOF-OF-CONCEPT DATA FOR COXSACKIEVIRUS B VACCINE

Provention Bio, Inc. | May 19, 2020

The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models. Results provide a solid scientific basis for human trials with Provention's PRV-101 vaccine. Read More

news image

EX-PFIZER ONCOLOGY R&D LEAD LANDS AT FIERCE 15 WINNER VIVIDION THERAPEUTICS

FierceBiotech | February 11, 2020

Pfizer’s former longtime cancer research head Robert Abraham, Ph.D., has become the new chief scientific officer at a San Diego biotech after leaving the Big Pharma last year. He moves over to 2017 Fierce 15 winner Vividion Therapeutics, a biotech looking to increase the number of proteins small molecules can target. Last April, it got off a $82 million series B financing round. Its platform is based on the work of Benjamin Cravatt, Phil Baran and Jin-Quan Yu at the Scripps Research Instit...

Read More
news image

INDUSTRIAL IMPACT

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More